Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876493 | 0.83 | CYP1A2 (0.59) | ESR1ESR2SLC7A5CYP1A2ACE | |
| SCHEMBL6379983 | 0.83 | CYP1A2 (0.59) | ESR1ESR2SLC7A5CYP1A2ACE | |
| SCHEMBL1709339 | 0.83 | CYP1A2 (0.64) | CYP1A2MMECPA1PPARG | |
| SCHEMBL1709283 | 0.83 | CYP1A2 (0.64) | CYP1A2MMECPA1PPARG | |
| SCHEMBL3661382 | 0.83 | CYP1A2 (0.59) | ESR1ESR2SLC7A5CYP1A2ACE | |
| SCHEMBL11308492 | 0.81 | ESR1 (0.50) | ESR1ESR2SLC7A5TAAR1SLC6A2 | |
| SCHEMBL107523 | 0.79 | ESR1 (0.49) | ESR1ESR2SLC7A5TAAR1SLC6A2 | |
| SCHEMBL106905 | 0.79 | TAAR1 (0.52) | ESR1ESR2SLC7A5TAAR1SLC6A2 | |
| SCHEMBL3662079 | 0.79 | ESR1 (0.61) | ESR1ESR2PPARG | |
| SCHEMBL13078733 | 0.79 | ESR1 (0.61) | ESR1ESR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ESR1 3597/4885ESR2 862/4885SLC7A5 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.